Porton Pharma's majority-owned subsidiary Suzhou Porton Biopharmaceuticals has obtained a Drug Manufacturing License issued by the Jiangsu Medical Products Administration for the first time. The license signifies that Suzhou Porton now has the compliance qualifications to undertake commercial contract manufacturing of cell and gene therapy products, which will help facilitate the company's related business development. In the first quarter of 2026, Porton Pharma achieved revenue of 886 million yuan and a net profit attributable to the parent company of 27.87 million yuan.
Porton Fine Chemicals LtdSubsidiary obtains drug manufacturing license, enabling commercial CGT production.
Suzhou Porton receives its first drug manufacturing license for CGT products.